Fosun Pharma: The subsidiary's drug approved for clinical trials

2026-04-09 15:41:36

Fosun Pharma Announcement: The controlling subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of FXB0871 for the treatment of locally advanced or metastatic solid tumors. FXB0871 is a PD-1 targeted IL-2 fusion protein developed in collaboration between the Group and Teva Pharmaceutical Industries Ltd., with the Group holding exclusive rights for development, manufacturing, and commercialization in China and the agreed Southeast Asian countries and regions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes